Ambu A/S: peers
Ambu A/S beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Ambu A/S, Demant A/S, Coloplast A/S, ConvaTec Group PLC, Bonesupport Holding AB (publ), Getinge AB: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Ambu A/Sbase AMBU-B.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Demant A/S DEMANT.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Coloplast A/S COLO-B.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | ConvaTec Group PLC CTEC.L · 🇬🇧 GB Percentile in Healthcare Percentile in UK | NovoCure Limited NVCR · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Bonesupport Holding AB (publ) BONEX.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Getinge AB GETI-B.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | AtriCure, Inc. ATRC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $3.2 BAug 1, 2026 · Market data5th of 8 | $9.5 BAug 1, 2026 · Market data2nd of 8 | $15.4 BAug 1, 2026 · Market data1st of 8 | $6.1 BAug 1, 2026 · Market data4th of 8 | $1.5 BOct 30, 2026 · Market data7th of 8 | $1.5 BAug 1, 2026 · Market data8th of 8 | $7.0 BAug 1, 2026 · Market data3rd of 8 | $3.1 BOct 29, 2026 · Market data6th of 8 | $4.6 B8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | $2.4 BFY2025 · ESEF2nd of 4 | $655 MFY2025 · SEC3rd of 4 | —— | $3.6 BFY2025 · ESEF1st of 4 | $535 MFY2025 · SEC4th of 4 | $1.5 B4 ranked |
| Net income (Higher is better) | —— | —— | —— | $175 MFY2025 · ESEF2nd of 5 | $-136 MFY2025 · SEC5th of 5 | $14 MFY2025 · ESEF3rd of 5 | $230 MFY2025 · ESEF1st of 5 | $-11 MFY2025 · SEC4th of 5 | $14 M5 ranked |
| Employees (Better neither way: ranked highest first) | 3,500As on 2020 · Profile5th of 7 | 15,000As on 2019 · Profile2nd of 7 | 15,022As on June-2023 · Profile1st of 7 | 10,000As on 2023 · Profile4th of 7 | 1,023As on 2020 · Profile6th of 7 | —— | 11,056As on 2022 · Profile3rd of 7 | 875As on 2021 · Profile7th of 7 | 10,0007 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | +6.5%FY2025 · ESEF4th of 441st51st | +8.3%FY2025 · SEC2nd of 445th62nd | ———— | +8.2%FY2025 · ESEF3rd of 445th57th | +14.9%FY2025 · SEC1st of 459th71st | +8.2%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | +6.8%FY2025 · SEC2nd of 246th59th | ———— | ———— | +17.4%FY2025 · SEC1st of 268th82nd | +12.1%2 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | -7.5%FY2025 · ESEF3rd of 329th30th | ———— | +14.0%FY2025 · ESEF2nd of 356th55th | +48.4%FY2025 · ESEF1st of 375th86th | ———— | +14.0%3 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | 56.2%FY2025 · ESEF3rd of 446th74th | 74.5%FY2025 · SEC2nd of 474th93rd | ———— | 47.6%FY2025 · ESEF4th of 433rd67th | 75.0%FY2025 · SEC1st of 475th87th | 65.4%4 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | 13.0%FY2025 · ESEF1st of 478th62nd | -23.5%FY2025 · SEC4th of 440th8th | ———— | 10.8%FY2025 · ESEF2nd of 474th68th | -1.8%FY2025 · SEC3rd of 455th37th | 4.5%4 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | 7.2%FY2025 · ESEF1st of 474th62nd | -20.8%FY2025 · SEC4th of 442nd10th | ———— | 6.5%FY2025 · ESEF2nd of 472nd64th | -2.1%FY2025 · SEC3rd of 457th38th | 2.2%4 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | -11.6%FY2025 · SEC2nd of 241st8th | ———— | ———— | 9.0%FY2025 · SEC1st of 270th68th | -1.3%2 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | 10.9%FY2025 · ESEF2nd of 582nd63rd | -38.9%FY2025 · SEC5th of 549th9th | 18.1%FY2025 · ESEF1st of 589th81st | 7.4%FY2025 · ESEF3rd of 578th49th | -2.4%FY2025 · SEC4th of 571st39th | 7.4%5 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 226.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 38.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 19.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 34.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 105.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 24.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 210.1×price Oct 29, 2026 · Market dataonly one with it96th97th | 210.1×— |
| Price to sales (Better neither way: ranked highest first) | 4.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.1×price Oct 30, 2026 · Market data2nd of 234th34th | ———— | 1.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 5.3×price Oct 29, 2026 · Market data1st of 258th78th | 3.7×2 ranked |
| Price to book (Better neither way: ranked highest first) | 3.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 5.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 7.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.5×price Oct 30, 2026 · Market data2nd of 264th71st | 16.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 1.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 6.4×price Oct 29, 2026 · Market data1st of 273rd81st | 5.4×2 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | -4.9%price Oct 30, 2026 · Market data2nd of 254th25th | 1.5%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 1.5%price Oct 29, 2026 · Market data1st of 274th44th | -1.7%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | 0.6×FY2025 · SEC2nd of 257th48th | ———— | ———— | 0.1×FY2025 · SEC1st of 225th18th | 0.3×2 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | -6.9×FY2025 · SEConly one with it50th24th | ———— | ———— | ———— | -6.9×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | 3 of 9FY2025 · SEC2nd of 2 | —— | —— | 7 of 9FY2025 · SEC1st of 2 | 5.0 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | —— | 3 of 5FY2025 · Scorecard3rd of 5 | 7 of 22FY2025 · Scorecard5th of 5 | 3 of 3FY2025 · Scorecard1st of 5 | 4 of 5FY2025 · Scorecard2nd of 5 | 12 of 23FY2025 · Scorecard4th of 5 | 60% passed5 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 1 of 5FY2025 · Scorecard1st of 2 | —— | —— | 0 of 6FY2025 · Scorecard2nd of 2 | 10% passed2 ranked |
| Growth checks (Higher is better) | —— | —— | —— | 1 of 2FY2025 · Scorecard5th of 5 | 4 of 6FY2025 · Scorecard4th of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 2 of 2FY2025 · Scorecard1st of 5 | 5 of 6FY2025 · Scorecard3rd of 5 | 83% passed5 ranked |
| Profitability checks (Higher is better) | —— | —— | —— | 2 of 3FY2025 · Scorecard2nd of 5 | 0 of 5FY2025 · Scorecard5th of 5 | 2 of 2FY2025 · Scorecard1st of 5 | 2 of 3FY2025 · Scorecard2nd of 5 | 1 of 5FY2025 · Scorecard4th of 5 | 67% passed5 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | —— | 2 of 5FY2025 · Scorecard2nd of 2 | —— | —— | 5 of 5FY2025 · Scorecard1st of 2 | 70% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | —— | 0 of 1FY2025 · Scorecard2nd of 2 | —— | —— | 1 of 1FY2025 · Scorecard1st of 2 | 50% passed2 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | —— | 89.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | 105.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 97.6%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | —— | 2422026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | 2862026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 2642 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | +3.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 2 | —— | —— | +5.2 pp2026-Q2 against 2026-Q1 · 13F1st of 2 | +4.3 pp2 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Ambu A/S: How market caps are worked out; Demant A/S: How market caps are worked out; Coloplast A/S: How market caps are worked out; ConvaTec Group PLC: How market caps are worked out; NovoCure Limited: How market caps are worked out; Bonesupport Holding AB (publ): How market caps are worked out; Getinge AB: How market caps are worked out; AtriCure, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Ambu A/S | — | — | — |
| Demant A/S | — | — | — |
| Coloplast A/S | — | — | — |
| ConvaTec Group PLC | 13.0%FY2025 | 78th percentile in Healthcaremedian -7.7%, 674 companies | 62nd percentile in UKmedian 8.5%, 313 companies |
| NovoCure Limited | -23.5%FY2025 | 40th percentile in Healthcaremedian -7.7%, 674 companies | 8th percentile in UKmedian 8.5%, 313 companies |
| Bonesupport Holding AB (publ) | — | — | — |
| Getinge AB | 10.8%FY2025 | 74th percentile in Healthcaremedian -7.7%, 674 companies | 68th percentile in Swedenmedian 8.0%, 128 companies |
| AtriCure, Inc. | -1.8%FY2025 | 55th percentile in Healthcaremedian -7.7%, 674 companies | 37th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Ambu A/S | Demant A/S | Coloplast A/S | ConvaTec Group PLC | NovoCure Limited | Bonesupport Holding AB (publ) | Getinge AB | AtriCure, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | $2.4 BESEF2nd | $655 MSEC3rd | — | $3.6 BESEF1st | $535 MSEC4th |
| 2024 | — | — | — | $2.3 BESEF2nd | $605 MSEC3rd | — | $3.3 BESEF1st | $465 MSEC4th |
| 2023 | — | — | — | — | $509 MSEC1st | — | — | $399 MSEC2nd |
| 2022 | — | — | — | — | $538 MSEC1st | — | — | $330 MSEC2nd |
| 2021 | — | — | — | — | $535 MSEC1st | — | — | $274 MSEC2nd |
| 2020 | — | — | — | — | $494 MSEC1st | — | — | $207 MSEC2nd |
| 2019 | — | — | — | — | $351 MSEC1st | — | — | $231 MSEC2nd |
| 2018 | — | — | — | — | $248 MSEC1st | — | — | $202 MSEC2nd |
| 2017 | — | — | — | — | $177 MSEC1st | — | — | $175 MSEC2nd |
| 2016 | — | — | — | — | $83 MSEC2nd | — | — | $155 MSEC1st |
| 2015 | — | — | — | — | $33 MSEC2nd | — | — | $130 MSEC1st |
| 2014 | — | — | — | — | $15 MSEC2nd | — | — | $107 MSEC1st |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Ambu A/S#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Demant A/SDEMANT.CO · 🇩🇰 DenmarkSame industry: Medical Instruments · Similar size: $9.5 B market cap against $3.2 B · Same country: Denmark · Ratios of the last two fiscal years on fileMarket cap $9.5 B (Aug 1, 2026) · revenue $3.6 B (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)In the group
- Coloplast A/SCOLO-B.CO · 🇩🇰 DenmarkSame industry: Medical Instruments · Similar size: $15.4 B market cap against $3.2 B · Same country: Denmark · Ratios of the last two fiscal years on fileMarket cap $15.4 B (Aug 1, 2026) · revenue $4.3 B (year to September 2024)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)In the group
- ConvaTec Group PLCCTEC.L · 🇬🇧 UKSame industry: Medical Instruments · Similar size: $6.1 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $6.1 B (Aug 1, 2026) · revenue $2.4 B (year to December 2025)88 of 100 (industry or sector 50 + size 26 + country 7 + figures on file 5)In the group
- NovoCure LimitedNVCR · 🇬🇧 UKSame industry: Medical Instruments · Similar size: $1.5 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $1.5 B (Oct 30, 2026) · revenue $655 M (year to December 2025)87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)In the group
- Bonesupport Holding AB (publ)BONEX.ST · 🇸🇪 SwedenSame industry: Medical Instruments · Similar size: $1.5 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $1.5 B (Aug 1, 2026)87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)In the group
- Getinge ABGETI-B.ST · 🇸🇪 SwedenSame industry: Medical Instruments · Similar size: $7.0 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $7.0 B (Aug 1, 2026) · revenue $4.4 B (year to December 2025)87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)In the group
- AtriCure, Inc.ATRC · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.1 B market cap against $3.2 B · Ratios of the last two fiscal years on fileMarket cap $3.1 B (Oct 29, 2026) · revenue $535 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Elekta AB (publ)EKTA-B.ST · 🇸🇪 SwedenSame industry: Medical Instruments · Similar size: $2.3 B market cap against $3.2 B · Same region: Northern EuropeMarket cap $2.3 B (Aug 1, 2026) · revenue $1.4 B (year to April 2022)85 of 100 (industry or sector 50 + size 28 + country 7)+ Add
- Biotage ABBIOT.ST · 🇸🇪 SwedenSame industry: Medical Instruments · Similar size: $1.0 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $1.0 B (last known, Jan 5, 2024) · revenue $195 M (year to December 2024)85 of 100 (industry or sector 50 + size 23 + country 7 + figures on file 5)+ Add
- AddLife AB (publ)ALIF-B.ST · 🇸🇪 SwedenSame industry: Medical Instruments · Similar size: $2.1 B market cap against $3.2 B · Same region: Northern EuropeMarket cap $2.1 B (Aug 1, 2026) · revenue $847 M (year to December 2021)84 of 100 (industry or sector 50 + size 27 + country 7)+ Add
- Envista Holdings CorporationNVST · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.8 B market cap against $3.2 B · Ratios of the last two fiscal years on fileMarket cap $3.8 B (Oct 28, 2026) · revenue $2.7 B (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
- Pulse Biosciences, Inc.PLSE · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.9 B market cap against $3.2 B · Ratios of the last two fiscal years on fileMarket cap $3.9 B (Oct 27, 2026) · revenue $0 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.